Azacitidine Accord 25 mg/mL powder for suspension for injection
Sponsors
Fondazione Gimema Franco Mandelli Onlus, Sellas Life Sciences Group Inc.
Conditions
Acute myeloid leukemia (AML) in second or later complete remission (CR2) or
second or later complete remission with incomplete platelet recovery (CRp2)Higher-risk-myelodysplastic syndromes
Phase 3
Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk-myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemotherapy, according to the BM-blast proportion (ACROBAT trial). MDS0519
RecruitingCTIS2023-510515-19-00
Start: 2020-11-27Target: 274Updated: 2025-08-27
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Active, not recruitingCTIS2024-516405-23-00
Start: 2021-06-08Target: 101Updated: 2025-01-16